Patent ID: 9326973
Filing Date: 2016-05-03
CPC Classification: A61K,A61P,C07D

Claim Text:
1. A combination comprising an NS5A-targeting compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein L is absent or selected from C A is absent or selected from isoquinolinyl, naphthyl, phenyl, pyrazinyl, pyridinyl, pyrimidinyl, and quinolinyl; B is selected from anthracenyl, benzofuranyl, bicycloalkyl, indanyl, indolyl, naphthyl, phenyl, pyridinyl, pyrimidinyl, pyrazinyl, tetrahydronaphthyl, thienyl, and each X is independently selected from O and NR each R each R R each R each R each R each R wherein R and R′ are each alkyl, or, together with the carbon atom to which they are attached, form a five- or six-membered ring optionally containing one oxygen or nitrogen atom; or R R and an NS5A synergist of formula (VII): or a pharmaceutically acceptable salt thereof, wherein: L is absent or selected from —O—, —CH A is selected from aryl, cycloalkenyl, and heteroaryl; B is selected from aryl, bicycloalkyl, cycloalkenyl, and heteroaryl; each R each m is independently 0, 1, or 2; each X is independently selected from CH each R R each R each R each R each R each R which, when administered, provides synergistic anti-HCV activity against variants that contain mutation(s) conferring resistance to the NS5A-targeting compound alone.